Wu, Yiquan
Wang, Victoria
Yarchoan, Robert
Funding for this research was provided by:
National Cancer Institute (ZIA BC010885)
Article History
Received: 25 August 2023
Accepted: 13 February 2024
First Online: 19 February 2024
Competing interests
: R. Yarchoan reports receiving research support and pacritinib for laboratory use in these studies from CTI BioPharma Corp., a Sobi Company, through and M-CRADA and CRADA with the NCI, and that this manuscript underwent a courtesy review from CTI BioPharma Corp. Dr. Yarchoan also reports receiving research support from Celgene (now Bristol Myers Squibb), Janssen Pharmaceuticals through CRADAs with the NCI and drugs for clinical trials from Merck, EMD-Serano, PDS Biotech, and Eli Lilly through CRADAs with the NCI. R. Yarchoan is a co-inventor on US Patent 10,001,483 entitled "Methods for the treatment of Kaposi's sarcoma or KSHV-induced lymphoma using immunomodulatory compounds and uses of biomarkers." An immediate family member of R. Yarchoan is a co-inventor on patents or patent applications related to internalization of target receptors, epigenetic analysis, and ephrin tyrosine kinase inhibitors. All rights, title, and interest to these patents have been assigned to the U.S. Department of Health and Human Services; the government conveys a portion of the royalties it receives to its employee inventors under the Federal Technology Transfer Act of 1986 (P.L. 99-502). All other authors declare no competing interests.